{"id":48663,"date":"2022-09-21T17:01:57","date_gmt":"2022-09-21T15:01:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/"},"modified":"2022-09-21T17:01:57","modified_gmt":"2022-09-21T15:01:57","slug":"aspect-biosystems-appoints-three-new-board-members","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/","title":{"rendered":"Aspect Biosystems Appoints Three New Board Members"},"content":{"rendered":"
\n

\nNew board members bring significant leadership experience in the biotech sector\n<\/p>\n

<\/a><\/p>\n

VANCOUVER, British Columbia–(BUSINESS WIRE)–#Biomanufacturing<\/a>–Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, is pleased to announce the appointment of three new members to its Board of Directors: Dr. Nancy Krieger, Dr. Don Haut, and Dr. Devyn Smith.\n<\/p>\n

\n\u201cI am excited to extend a warm welcome to Nancy, Don, and Devyn as they join Aspect\u2019s Board of Directors,\u201d said Tamer Mohamed, Chief Executive Officer, Aspect Biosystems. \u201cEach of them brings substantial experience in regenerative medicine and we are thrilled to have them join our mission as we move towards the next stage of growth.\u201d\n<\/p>\n

\nAbout Aspect\u2019s New Board Members<\/b>\n<\/p>\n

\nDr. Nancy Krieger <\/b>is the Chief Medical Officer of Talaris Therapeutics, a recently public late-clinical stage cell therapy biotech. She has over 18 years of global experience in the biopharmaceutical industry, including leadership positions at Bristol Myers Squibb and Novartis in areas spanning solid organ and stem cell transplantation, immunology, rare disorders, and chronic kidney and liver diseases. Before joining industry, Dr. Krieger had an active practice in liver transplantation as well as a basic science laboratory. She completed her transplant fellowship at the University of Wisconsin and general surgical residency at Stanford University, including a postdoctoral fellowship in Stanford\u2019s immunology department. Dr. Krieger earned her MD at Columbia University College of Physicians and Surgeons.\n<\/p>\n

\n\u201cI am thrilled to be joining the Board of Aspect Biosystems,\u201d said Dr. Nancy Krieger. \u201cAs a transplant surgeon I am passionate about the tremendous potential of Aspect\u2019s 3D bioprinting technology for regenerative cellular therapies, with the ultimate possibility of replacing organ transplants without the need for life-long immunosuppression.\u201d\n<\/p>\n

\nDr. Don Haut<\/b> is currently the CEO of Carmine Therapeutics, a discovery-stage, non-viral gene therapy company with operations in Boston and Singapore. Throughout his career, Dr. Haut has completed transactions exceeding $8 billion. As Chief Business Officer of AskBio, he led the firm\u2019s business development activities and spearheaded AskBio\u2019s $4 billion acquisition by Bayer AG. Originally trained as a molecular biologist before joining McKinsey, Dr. Haut has since held senior business roles at 3M Company, Smith & Nephew, The Medicines Company, Promedior, Histogenics, Sherlock Bio, and AskBio. He earned his PhD in Molecular Biology from the Medical School at the University of Missouri-Columbia, and an MBA from Washington University\u2019s Olin School of Business.\n<\/p>\n

\n\u201cWhen I first learned about what Aspect Biosystems was doing, my first thought was \u2018Wow!\u2019\u201d said Dr. Don Haut. \u201cMy second thought was \u2018it would be great to work with those folks \u2013 they are really onto something.\u2019 So, I am delighted to be joining Aspect \u2013 the team, the technology, and the mission are all outstanding.”\n<\/p>\n

\nDr. Devyn Smith<\/b> joined Arbor Biotechnologies as CEO in 2021 after concluding his role as COO of Sigilon Therapeutics. Prior to Sigilon, Dr. Smith worked in a variety of roles at Pfizer Inc., including COO of the UK-based Neusentis Unit focused on discovering and developing cell therapies. He received his PhD in Genetics from Harvard Medical School. He is an inventor on multiple patents and has published in leading scientific journals throughout his career. Dr. Smith is a board member and officer for the Alliance for Regenerative Medicine, the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.\n<\/p>\n

\n\u201cI am excited to join the board of Aspect Biosystems,\u201d said Dr. Devyn Smith. \u201cI look forward to partnering with Tamer and the talented team at Aspect to build a successful company that delivers novel cellular therapies to patients with high unmet needs.\u201d\n<\/p>\n

\nFor full list of board members, visit www.aspectbiosystems.com\/about<\/a>.\n<\/p>\n

\nAbout Aspect Biosystems<\/b>\n<\/p>\n

\nAspect Biosystems is a biotechnology company creating bioprinted tissue therapeutics to transform how we treat disease. Aspect is combining its proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design to create a pipeline of allogeneic tissues that replace or repair damaged organ functions. The company is also partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine. Learn more at aspectbiosystems.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nNatalie Korenic
\n
Aspect Biosystems
\n
+1-604-263-0502
\n
media@aspectbiosystems.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

New board members bring significant leadership experience in the biotech sector VANCOUVER, British Columbia–(BUSINESS WIRE)–#Biomanufacturing–Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, is pleased to announce the appointment of three new members to its Board of Directors: Dr. Nancy Krieger, Dr. Don Haut, and Dr. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48663","6":"format-standard","7":"category-industry"},"yoast_head":"\nAspect Biosystems Appoints Three New Board Members - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aspect Biosystems Appoints Three New Board Members - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"New board members bring significant leadership experience in the biotech sector VANCOUVER, British Columbia–(BUSINESS WIRE)–#Biomanufacturing–Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, is pleased to announce the appointment of three new members to its Board of Directors: Dr. Nancy Krieger, Dr. Don Haut, and Dr. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-21T15:01:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220921005348\/en\/1578386\/21\/Aspect_Biosystems_Square_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aspect-biosystems-appoints-three-new-board-members\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aspect-biosystems-appoints-three-new-board-members\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Aspect Biosystems Appoints Three New Board Members\",\"datePublished\":\"2022-09-21T15:01:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aspect-biosystems-appoints-three-new-board-members\\\/\"},\"wordCount\":703,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aspect-biosystems-appoints-three-new-board-members\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220921005348\\\/en\\\/1578386\\\/21\\\/Aspect_Biosystems_Square_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aspect-biosystems-appoints-three-new-board-members\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aspect-biosystems-appoints-three-new-board-members\\\/\",\"name\":\"Aspect Biosystems Appoints Three New Board Members - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aspect-biosystems-appoints-three-new-board-members\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aspect-biosystems-appoints-three-new-board-members\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220921005348\\\/en\\\/1578386\\\/21\\\/Aspect_Biosystems_Square_logo.jpg\",\"datePublished\":\"2022-09-21T15:01:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aspect-biosystems-appoints-three-new-board-members\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aspect-biosystems-appoints-three-new-board-members\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aspect-biosystems-appoints-three-new-board-members\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220921005348\\\/en\\\/1578386\\\/21\\\/Aspect_Biosystems_Square_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220921005348\\\/en\\\/1578386\\\/21\\\/Aspect_Biosystems_Square_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aspect-biosystems-appoints-three-new-board-members\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aspect Biosystems Appoints Three New Board Members\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aspect Biosystems Appoints Three New Board Members - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/","og_locale":"en_US","og_type":"article","og_title":"Aspect Biosystems Appoints Three New Board Members - Pharma Trend","og_description":"New board members bring significant leadership experience in the biotech sector VANCOUVER, British Columbia–(BUSINESS WIRE)–#Biomanufacturing–Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, is pleased to announce the appointment of three new members to its Board of Directors: Dr. Nancy Krieger, Dr. Don Haut, and Dr. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-21T15:01:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220921005348\/en\/1578386\/21\/Aspect_Biosystems_Square_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Aspect Biosystems Appoints Three New Board Members","datePublished":"2022-09-21T15:01:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/"},"wordCount":703,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220921005348\/en\/1578386\/21\/Aspect_Biosystems_Square_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/","url":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/","name":"Aspect Biosystems Appoints Three New Board Members - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220921005348\/en\/1578386\/21\/Aspect_Biosystems_Square_logo.jpg","datePublished":"2022-09-21T15:01:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220921005348\/en\/1578386\/21\/Aspect_Biosystems_Square_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220921005348\/en\/1578386\/21\/Aspect_Biosystems_Square_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/aspect-biosystems-appoints-three-new-board-members\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Aspect Biosystems Appoints Three New Board Members"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48663"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48663\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48663"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48663"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}